Schrodinger Inc at Credit Suisse Healthcare Innovators Series : AI/Biotech Event Transcript
Thank you. Good afternoon, everyone, and welcome to the second panel of the Credit Suisse Healthcare Innovator Series focused on the intersection of drug discovery, development and artificial intelligence. Thank you, everyone, for joining for this very exciting topic today. This is Jason English from the Healthcare Investment Banking team here at CS, where I focus on health care technology and pharma outsourcing solutions. And I'm joined by John Hoffman, another Managing Director from our equity capital markets team, where he leads our biopharma and health care technology effort.
As you may have seen this morning, our panel this afternoon, will have a very similar format, a coffee shop type style where we'll try to keep it more conversational and hopefully, lively for everyone. But with that, let me make some brief introductions for our distinguished panelists that we have with us today.
First, we have Anne Wojcicki, CEO and Co-founder of 23andMe. A little different than maybe what you see on her screen. She doesn't work for AbCellera. Anne is a pioneer in the direct-to-consumer
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |